ReproCell Stock

ReproCell Equity Ratio

The Equity Ratio of ReproCell (4978.T) as of Sep 4, 2026 is 92.91 %. In the previous year, Equity Ratio was 91.81 % — a change of 1.19% (higher).

Equity Ratio

92.91 %

YoY

1.19%

Last updated:

Equity Ratio of ReproCell is 2026 92.91 % . Equity Ratio of ReproCell was 2025 91.81 % . It decreases by 1.19% higher compared to the previous year.

The ReproCell Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
94.70 JPY
Jan 1, 2019
94.39 JPY
Jan 1, 2020
92.33 JPY
Jan 1, 2021
89.04 JPY
Jan 1, 2022
89.57 JPY
Jan 1, 2023
90.66 JPY
Jan 1, 2024
91.81 JPY
Jan 1, 2025
92.91 JPY
The ReproCell Equity Ratio history
YEAREquity RatioYoY
92.91 %+1.19%
91.81 %+1.28%
90.66 %+1.22%
89.57 %+0.60%
89.04 %-3.57%
92.33 %-2.18%
94.39 %-0.33%
94.70 %+0.95%
93.82 %+2.86%
91.21 %-2.24%
93.30 %-2.69%
95.88 %
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Equity Ratio of ReproCell is 92.91 % in 2026.

Equity Ratio of ReproCell changed from 91.81 % to 92.91 %, representing a 1.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio ReproCell since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's ReproCell with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — ReproCell

All Key Metrics — ReproCell